Abstracts

707 – Identification and Characterization of Novel Chemical Scaffolds With Anti-HIV Activities

Background HIV-1 protease (PR) is initially synthesized as part of the Gag-Pol polyprotein precursor, which undergoes regulated autoprocessing to produce free mature PR, essential for viral particle maturation and infectivity. We previously demonstrated that precursors and mature PRs have distinct enzymatic properties, as precursors are up to 1,000-fold less-sensitive to protease inhibitors (PIs) compared to…

706 – Development of a 2-Drug Long-Acting Removable Formulation for HIV Suppression

Background Non-adherence to HIV treatment increases the risk of viral rebound and the development of drug resistance. Long-acting formulations have shown improved compliance compared with conventional regimens requiring frequent dosing, leading to better outcomes and treatment continuation. Here, an in situ forming implant system (ISFI) was used to develop a long-acting (LA) formulation that can co-deliver two drugs…

665 – Effect of 12-Month Switch to Dual cART on T-Cell Homeostasis, Gut and Mitochondrial Damage

Background Residual immune activation/inflammation is a hallmark of treated HIV. Dual (2DR) regimens are efficacious in maintaining viral suppression, however, their effect on T-cell homeostasis and mitochondrial damage, is ill-defined. Methods PLWH switching from viro-suppressive, three drug (3DR) cART to an INSTI-based 2DR with sample availability (at switch and approximately 12 months from switch) were…

678 – Long-Acting Cabotegravir/Rilpivirine in Real Life: Sex-Based Characteristics, PROs, and Effectiveness

Background This study aimed to focus on sex-based characteristics, patient reported outcomes (PROs) and effectiveness in people with HIV switching to long-acting cabotegravir-rilpivirine (LA-CAB/RPV) administered Q2M in Hospital Clínic of Barcelona, Spain. Methods People starting LA-CAB/RPV were invited to participate in an observational, prospective study approved by the local Ethical Committee. Clinical information was routinely…

681 – Low-Level Viremia and Risk Factors for Failure on Long-Acting Cabotegravir/Rilpivirine (LA CAB/RPV)

Background LA CAB/RPV has transformed the HIV treatment paradigm as an alternative to daily oral antiretroviral therapy (ART). Potential challenges with CAB/RPV include therapeutic failures characterized by virologic failure and/or the development of resistance-associated mutations (RAMs). Methods This was a single-center, retrospective cohort study of adults with HIV on LA CAB/RPV at the Ohio State…

688 – First Year of Lenacapavir Long-Acting Injectable Use in the OPERA Cohort

Background Lenacapavir (LEN), a first in class capsid inhibitor approved by the FDA (22DEC2022) as a twice yearly long-acting injectable used with an optimized background regimen (OBR), is indicated for heavily treatment-experienced individuals with multidrug resistant HIV-1 infection who are failing their current antiretroviral therapy (ART) regimen due to resistance, intolerance, or safety concerns. We…

694 – Forgiveness of Dolutegravir-Based Regimens Using Medication Possession Ratio: Andhra Pradesh, India

Background Adherence to antiretroviral therapy (ART) is independently associated with viral load (VL) suppression among people living with HIV (PLHIV). Previous studies have demonstrated that dolutegravir-based regimens (DBR) have forgiveness for strict adherence to achieve VL suppression (VLS) as measured by pharmacy refill and electronic drug monitoring, where 75% and 80% adherence, respectively, can achieve…